Th-P16:308 The effect of hypolipidaemic drugs on lipoprotein-associated phospholipase A2 (LP-PLA2) activity and mass

Saougos, Vasilios G.; Kostapanos, Michael S.; Kalogirou, M.; Tselepis, A.; Elisaf, Moses

doi:10.1016/s1567-5688(06)82266-x

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…47 The hs-CRP lowering effect of rosuvastatin is in addition to reduction of the levels of other inflammatory markers, such as von Willebrand factor (vWF), fibrinogen, and serum amyloid A and platelet activating factor acetylhydrolase (PAFAH). 33,48,49 We have recently shown that rosuvastatin treatment decreases plasma levels of visfatin, an adipokine mostly associated with the visceral fat and may have proinflammatory properties. 50 Independently of its lipid-lowering capacity, rosuvastatin has been shown to decrease the expression and/or plasma levels of various proinflammatory cytokines, such as tumor necrosis factor-α (TNFα), 48,51,52 interleukin (IL)-6, 46,52 IL-8, 52,53 interferon-γ (IFNγ), 51 CD40, 54 soluble CD40 ligand (sCD40L), 46 and cyclooxyganase (COX)-2.…”

Section: Anti-inflammatory and Immunomodulatory Effectsmentioning

confidence: 99%

An Overview of the Extra-Lipid Effects of Rosuvastatin

Kostapanos

Milionis

Elisaf

2008

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

Statins, in addition to their beneficial lipid modulation effects, exert a variety of several so-called "pleiotropic" actions that may result in clinical benefits. Rosuvastatin, the last agent of the class to be introduced, has proved remarkably potent in reducing low-density lipoprotein cholesterol levels. At present, no large-scale primary or secondary prevention clinical trials document either its long-term safety or its effectiveness in preventing cardiovascular events. A substantial number of experimental and clinical studies have indicate favorable effects of rosuvastatin on endothelial function, oxidized low-density lipoprotein, inflammation, plaque stability, vascular remodeling, hemostasis, cardiac muscle, and components of the nervous system. Available data regarding the effects of rosuvastatin on renal function and urine protein excretion do not seem to raise any safety concerns. Whether the established "pleiotropy" and/or lipid-lowering efficacy of rosuvastatin may translate into reduced morbidity and mortality remains to be shown in ongoing clinical outcome trials.

show abstract